ScreenerHero

OMEROmeros Corporation

NAS · US · Healthcare · Biotechnology · omeros.com
19.27USD+4.79%Mkt Cap: 1.39B $P/E: 11.68

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead p…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap1.39B $
Enterprise Value1.51B $
Revenue (TTM)38.42M $
Gross Profit14.73M $
Net Income (TTM)-3.35M $
Revenue/Share0.5460 USD
Last Price19.27 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees175
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS6821431029
Valuation
P/E (Trailing)11.68
P/E (Forward)16.27
PEG0.81
EV/EBITDA-21.05
EV/Revenue39.39
P/S35.10
P/B-26.17
EPS (TTM)1.67
EPS (Forward)1.15
52W Range
3.94098% of range19.58
52W High19.58 USD
52W Low3.940 USD
Profitability
Gross Margin38.34%
Oper. Margin0.26%
EBITDA Margin-187.17%
Profit Margin324.88%
ROE2.76%
ROA-1.03%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-116.09M $
CapEx (TTM)65.00K $
FCF Margin477.10%
FCF Yield13.14%
Net Debt164.92M $
Net Debt/EBITDA-2.29
Balance Sheet
Debt/Equity-1.97
Current Ratio1.95
Quick Ratio1.61
Book Value/Sh-0.7120 USD
Cash/Share1.823 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating2.3 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)33.00 USD
Upside (mean)+71.3%
Target Range33.00 USD – 33.00 USD
# Analysts1
Ownership
Shares Out.72.39M
Float69.81M
Insiders4.08%
Institutions50.48%
Short Interest
Short Ratio10.5d
Short % Float22.09%
Short % Out.21.31%
Shares Short15.42M
Short (prev mo.)15.14M
Technical
SMA 5011.53 (+67.1%)
SMA 20011.49 (+67.8%)
Beta2.54
S&P 52W Chg18.16%
Avg Vol (30d)2.03M
Avg Vol (10d)3.37M
Technical Indicators
RSI (14)86.7
MACD1.9681
MACD Signal1.3326
MACD Hist.+0.6355
BB Upper19.17 USD
BB Middle13.66 USD
BB Lower8.143 USD
BB Width80.77%
ATR (14)1.007 USD
Vol Ratio (20d)1.09x